Science:Life Sciences
Much has been made about a cancer moonshot, but in the world of oncology, rocket fuel is rarely a topic of conversation except maybe as a metaphor. EpicentRx, though, is looking to rocket fuel as a source for its lead experimental therapy RRx-001. It believes this high-energy molecule, derived from rocket fuel, has the potential to improve immunotherapies and radiotherapies, as well as having anticancer activity on its own. We spoke to Corey Carter, president and CEO of EpicentRx about how RRx-001 came about, how it works, and the company’s oncolytic viral pipeline also in development.
view more
More Episodes
Democratizing Drug Discovery
2021-09-30
2021-09-30
Scaling Genetic Counseling Services with AI
2021-09-23
2021-09-23
Striking Hepatitis B at Its Core
2021-09-02
2021-09-02
Building a Better Path to Neurotherapeutics
2021-08-12
2021-08-12
Engineering Life to Reach New Worlds
2021-07-29
2021-07-29
Mapping the Universe of Human Proteins
2021-07-15
2021-07-15
A Test for Data-Driven Drug Development
2021-06-10
2021-06-10
Get this podcast on your
phone, FREE
